Ponatinib, a leukemia drug, damages the heart by activating a protein called PGAM5 that breaks down mitochondria—the cell’s power plants. According to Gram Research analysis, mice without PGAM5 were protected from ponatinib-induced heart damage, suggesting that blocking this protein could prevent cardiotoxicity. The drug works by causing abnormal clumping of a mitochondrial protein (VDAC1), which simultaneously shuts down two cellular defense systems, leading to mitochondrial failure and heart dysfunction.
Ponatinib is a powerful drug that helps people with a specific type of leukemia survive, but it can seriously damage the heart. According to Gram Research analysis, scientists discovered exactly how this happens: the drug triggers a protein called PGAM5 that breaks down the heart’s cellular power plants (mitochondria). When these mitochondria fail, the heart can’t pump properly. The good news? Researchers found that blocking PGAM5 in mice prevented heart damage from ponatinib, suggesting a potential way to make this life-saving cancer drug safer for patients.
Key Statistics
A 2026 research study in mice found that ponatinib markedly increased PGAM5 expression in the heart and induced contractile dysfunction, inflammatory activation, and cardiomyocyte apoptosis, all of which were substantially attenuated in genetically modified mice lacking PGAM5.
Research published in 2026 demonstrated that forced VDAC1 oligomerization with arsenic trioxide largely abolished the protective effects of PGAM5 deficiency, confirming VDAC1 clumping as the critical downstream event in ponatinib-induced cardiotoxicity.
A 2026 mechanistic study revealed that ponatinib-induced PGAM5 activation simultaneously suppressed both PINK1/Parkin-related mitophagy and the mitochondrial unfolded protein response, resulting in mitochondrial fragmentation, oxidative stress, and impaired bioenergetic function in heart cells.
The Quick Take
- What they studied: How ponatinib, a leukemia drug, damages the heart and whether blocking a specific protein (PGAM5) could prevent that damage
- Who participated: Genetically modified mice with and without the PGAM5 protein, plus laboratory heart cells, to test whether PGAM5 is responsible for heart damage
- Key finding: Mice without PGAM5 were protected from ponatinib’s heart damage, while normal mice developed serious heart problems. This shows PGAM5 is the key culprit.
- What it means for you: If you or a loved one takes ponatinib for leukemia, this research suggests doctors may eventually have a way to protect your heart. However, this is still early research in animals—human treatments are years away.
The Research Details
Scientists created special mice that lacked the PGAM5 protein in their heart cells, then compared them to normal mice. Both groups were fed a high-fat diet and given ponatinib to see how their hearts responded. They measured heart function using ultrasound (echocardiography) and examined individual heart cells under microscopes. They also studied isolated heart cells in the lab to understand the exact molecular mechanisms—basically, they traced the chain of events from the drug entering the cell to the mitochondria breaking down.
The researchers used multiple approaches to confirm their findings: genetic studies in mice, laboratory cell experiments, and advanced genetic sequencing to see which genes were turned on or off. They also tested whether forcing mitochondrial damage in a different way (using arsenic) could overcome the protection from losing PGAM5, which helped prove that PGAM5 was truly responsible for the damage.
This research approach is important because it identifies the exact molecular mechanism—the step-by-step process—that causes ponatinib to damage hearts. Rather than just observing that the drug is toxic, the scientists pinpointed PGAM5 as the critical control switch. This matters because once you understand the mechanism, you can design drugs or treatments to block just that step, potentially allowing patients to keep taking ponatinib without heart damage.
This is a well-designed mechanistic study using multiple complementary approaches (animal models, cell cultures, molecular analysis). The use of genetically modified mice with loss-of-function studies (removing PGAM5) strengthens the evidence that PGAM5 actually causes the problem rather than just being associated with it. The confirmation using arsenic-induced damage further validates the findings. However, this is still preclinical research—the findings are in mice and lab cells, not yet in humans, so translation to clinical practice requires additional studies.
What the Results Show
Ponatinib caused significant heart dysfunction in normal mice, including reduced pumping ability, increased inflammation, and death of heart cells. In contrast, mice genetically engineered to lack PGAM5 in their heart cells were largely protected from these harmful effects. This dramatic difference shows that PGAM5 is essential for ponatinib to damage the heart.
At the molecular level, ponatinib activated PGAM5, which then caused abnormal clumping (oligomerization) of a mitochondrial protein called VDAC1. This clumping was the critical event that triggered mitochondrial dysfunction. When VDAC1 clumped together, it simultaneously shut down two protective systems: mitophagy (the cell’s ability to clean up damaged mitochondria) and the UPRmt (the cell’s stress response that repairs damaged proteins inside mitochondria). Without these two defense systems working, mitochondria accumulated damage, produced excessive harmful molecules called free radicals, and lost their ability to generate energy.
The researchers confirmed that VDAC1 clumping was truly the critical step by using arsenic trioxide to force VDAC1 to clump in PGAM5-deficient mice. When they did this, the protective effects of losing PGAM5 largely disappeared, proving that VDAC1 clumping is downstream of PGAM5 and is the actual cause of damage.
The study found that ponatinib increased oxidative stress (accumulation of harmful free radicals) in the heart, which was prevented by PGAM5 loss. Mitochondrial fragmentation (breaking apart of the cellular power plants) occurred in normal mice but not in PGAM5-deficient mice. Gene expression analysis revealed that ponatinib suppressed genes involved in mitochondrial quality control, and this suppression was reversed when PGAM5 was absent. These findings all point to a coordinated failure of mitochondrial maintenance systems as the mechanism of heart damage.
Previous research had shown that ponatinib causes heart damage through mitochondrial dysfunction, but the upstream trigger—what actually starts the cascade—was unknown. This study fills that gap by identifying PGAM5 and VDAC1 as the critical initiating factors. The finding that PGAM5 simultaneously disrupts two protective pathways (mitophagy and UPRmt) is novel and explains why ponatinib’s cardiotoxicity is so severe. This mechanistic insight goes beyond prior work that simply documented the damage.
This research was conducted entirely in mice and laboratory cells, not in humans. Mice may respond differently to drugs than people do. The study used a high-fat diet in mice, which may not perfectly replicate the conditions in ponatinib patients. The exact doses and exposure times in mice may not match real clinical scenarios. Additionally, while the study identifies PGAM5 as a target, it doesn’t yet demonstrate that blocking PGAM5 is safe in humans or that it wouldn’t interfere with ponatinib’s anti-cancer effects. Human clinical trials would be needed to determine if this approach is practical and safe.
The Bottom Line
If you are currently taking ponatinib: Continue taking your medication as prescribed by your oncologist—the benefits for treating leukemia are well-established and life-saving. However, discuss heart monitoring with your doctor, including regular echocardiograms and blood tests for heart damage markers. This research is preliminary and not yet ready for clinical application. If you are a researcher or pharmaceutical company: This study suggests that PGAM5 inhibitors or drugs that prevent VDAC1 oligomerization could be developed as companion therapies to protect the heart during ponatinib treatment. Further preclinical and clinical research is warranted.
Patients taking ponatinib for chronic myeloid leukemia with the T315I mutation should be aware of this research as it may lead to better heart protection strategies in the future. Oncologists and cardiologists treating these patients should monitor for heart dysfunction. Pharmaceutical companies developing new cancer drugs should consider this mechanism when designing tyrosine kinase inhibitors. Researchers studying mitochondrial dysfunction and drug toxicity will find this mechanistic pathway relevant.
This is fundamental research that has not yet reached human testing. If PGAM5-targeting drugs are developed, they would need to go through preclinical safety testing (1-2 years), then human clinical trials (3-7 years minimum), before becoming available to patients. Realistically, any clinical application is likely 5-10 years away. In the near term, this research may inform better heart monitoring strategies for current ponatinib patients.
Frequently Asked Questions
Is ponatinib safe for people with leukemia despite causing heart damage?
Ponatinib is highly effective for treating specific leukemia types and remains the standard treatment. Heart damage risk varies by individual. Regular heart monitoring (echocardiograms, blood tests) can detect problems early. Discuss your personal risk-benefit ratio with your oncologist, as the cancer-fighting benefits often outweigh heart risks for eligible patients.
When will PGAM5-blocking drugs be available to protect hearts from ponatinib?
This research is still in early stages using mice and lab cells. Developing a safe, effective PGAM5 inhibitor for humans requires several more years of testing. Realistically, any clinical application is 5-10 years away. Current ponatinib patients should focus on heart monitoring rather than waiting for this potential future therapy.
What can I do now if I’m taking ponatinib to protect my heart?
Follow your doctor’s heart monitoring schedule closely (regular echocardiograms and blood tests). Maintain a heart-healthy lifestyle: moderate exercise, low sodium diet, healthy weight, and stress management. Report new symptoms like shortness of breath or chest discomfort immediately. Work with both your oncologist and cardiologist to catch any heart changes early.
How does PGAM5 damage the heart at the cellular level?
PGAM5 causes a mitochondrial protein (VDAC1) to clump abnormally, which shuts down two cellular cleanup systems simultaneously: mitophagy (removing damaged mitochondria) and the stress response that repairs damaged proteins. Without these defenses, mitochondria accumulate damage, produce harmful free radicals, and fail to generate energy, causing heart cells to die.
Could blocking PGAM5 interfere with ponatinib’s cancer-fighting ability?
This study didn’t test whether PGAM5 blocking affects ponatinib’s anti-cancer effects. That’s a critical question for future research. Any potential therapy would need to protect the heart without reducing the drug’s ability to kill leukemia cells. This is why human clinical trials are essential before any clinical use.
Want to Apply This Research?
- If taking ponatinib, track weekly heart-related symptoms: shortness of breath during normal activity, unusual fatigue, chest discomfort, or swelling in legs/ankles. Rate each on a 0-10 scale and log the date. Share trends with your oncologist at appointments.
- Work with your care team to establish a heart-healthy routine: moderate aerobic exercise (as tolerated), reduce sodium intake, maintain a healthy weight, and avoid high-fat foods. Log these activities in the app to maintain accountability and share progress with your healthcare providers.
- Set reminders for scheduled heart function tests (echocardiograms, EKGs) recommended by your doctor. Track results over time in the app to visualize trends. Monitor for new or worsening symptoms between appointments. Share this data with your oncology and cardiology teams to enable early detection of any heart changes.
This article describes early-stage research conducted in mice and laboratory cells. These findings have not yet been tested in humans and should not be interpreted as medical advice. If you are taking ponatinib or any cancer medication, continue following your oncologist’s treatment plan and attend all scheduled heart monitoring appointments. Do not stop, change, or add medications based on this research without explicit guidance from your healthcare team. This research may eventually lead to new heart-protective strategies, but such treatments are not yet available. Always consult with your oncologist and cardiologist regarding your individual risk factors and treatment options.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.